This pilot research trial studies quantitative imaging metrics derived from contrast
enhanced computed tomography (CECT) in enhancing assessment of disease status in patients
with kidney cancer. Quantitative imaging is the extraction of quantifiable features from
radiological images for the assessment of disease status. Collecting quantitative imaging
metrics from CECT imaging may help doctors predict tumor aggressiveness and nuclear grade
(tumor stage) and assess treatment response and prognosis in cancer imaging.
I. To investigate the role of quantitative imaging metrics (QIM) as a potential DIAGNOSTIC
II. To investigate if QIM parameters can differentiate clear cell renal cell carcinoma (RCC)
from papillary RCC.
III. To evaluate the tumor grade of the target lesion as assessed by QIM from CECT for
agreement with the pathological (Fuhrman) grade.
IV. To investigate the role of QIM as a potential PROGNOSTIC biomarker. V. To develop a
novel method of calculating renal tumor contact surface area (CSA) using advanced
image-processing technology (MATLAB®, 3 dimension [D] Synapse) and predict peri-operative
variables such as blood loss, operative time and post-operative estimated glomerular
filtration rate (eGFR) in patients undergoing partial nephrectomy (PN).
VI. To develop QIM that would help in predicting postoperative functional outcomes such as
predicted surgically resected volume and postoperative glomerular filtration rate (GFR).
Patients' clinical and imaging data are collected from routine multiphase CECT imaging and
used to establish and validate the classification/prediction rule for QIM.
- Subjects with a renal mass who are scheduled for surgery for presumed RCC
- Subjects scheduled for standard of care contrast enhanced CT examination at USC
Norris Comprehensive Cancer Center
- Subjects competent to sign study specific written informed consent
- Subjects who are pregnant
- Subjects who cannot consent for themselves